title: Vitronectin modulates glycosaminoglycan dependent reactions of protein C inhibitor.
abstract: Protein C inhibitor (PCI), a glycosaminoglycan (GAG) dependent serine protease inhibitor, inhibits its target proteases by forming SDS-stable 1:1 complexes. GAGs alter target enzyme specificity of PCI in such a way that e.g. urokinase (uPA) is the preferred target enzyme in the presence of GAGs while in their absence preferentially tissue kallikrein (TK) complexes are formed. The effect of the GAG-binding adhesive glycoprotein vitronectin (Vn) on the GAG-stimulated inhibition of uPA by PCI was studied using an amidolytic assay. In the presence of heparin, Vn protected uPA from inhibition by PCI in a dose-dependent manner with respect to both, Vn- and heparin-concentration. Vn also was active when heparin was replaced by low-molecular weight heparin or heparan sulfate, respectively. In the absence of GAGs, Vn had no effect on the inhibition of uPA by PCI. In a similar system, Vn was far less effective in modifying the inhibitory function of heparin on the inhibition of TK by PCI. When equimolar concentrations of radiolabelled uPA and TK were incubated with PCI in the presence of heparin, only complexes of PCI with uPA were detectable. Addition of Vn reduced this complex formation, whereas, in contrast, complexes of PCI and TK appeared. These results indicate that Vn modulates both, the activity and specificity of PCI and suggest different structural heparin-requirements for the PCI/uPA versus PCI/TK interaction.
authors.affiliation: Department of Medical Physiology, University of Vienna, Austria.
authors.forename: D
authors.initials: D
authors.lastname: Seiffert
authors.forename: M
authors.initials: M
authors.lastname: Geiger
authors.forename: S
authors.initials: S
authors.lastname: Ecke
authors.forename: B R
authors.initials: BR
authors.lastname: Binder
mesh_terms: D000577:Amides / Q000378:metabolism; D001798:Blood Proteins / Q000502:physiology*; D006023:Glycoproteins / Q000502:physiology*; D006025:Glycosaminoglycans / Q000502:physiology*; D006801:Humans; D066298:In Vitro Techniques; D007457:Iodine Radioisotopes; D007610:Kallikreins / Q000652:urine; D015849:Plasminogen Inactivators / Q000502:physiology* / Q000652:urine; D018046:Protein C Inhibitor; D012680:Sensitivity and Specificity; D015842:Serine Proteinase Inhibitors / Q000502:physiology* / Q000652:urine; D020840:Tissue Kallikreins; D014568:Urokinase-Type Plasminogen Activator / Q000652:urine; D019096:Vitronectin
chemical_list: D000577:Amides; D001798:Blood Proteins; D006023:Glycoproteins; D006025:Glycosaminoglycans; D007457:Iodine Radioisotopes; D015849:Plasminogen Inactivators; D018046:Protein C Inhibitor; D015842:Serine Proteinase Inhibitors; D019096:Vitronectin; D007610:Kallikreins; D020840:Tissue Kallikreins; D014568:Urokinase-Type Plasminogen Activator